- Home
- ACHC vs LQDA Comparison
ACHC vs LQDA Comparison
Compare ACHC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHC
- LQDA
- Stock Information
- Founded
- ACHC 2005
- LQDA 2004
- Country
- ACHC United States
- LQDA United States
- Employees
- ACHC N/A
- LQDA N/A
- Industry
- ACHC Medical Specialities
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- ACHC Health Care
- LQDA Health Care
- Exchange
- ACHC Nasdaq
- LQDA Nasdaq
- Market Cap
- ACHC 1.7B
- LQDA 1.7B
- IPO Year
- ACHC N/A
- LQDA 2018
- Fundamental
- Price
- ACHC $19.24
- LQDA $20.45
- Analyst Decision
- ACHC Strong Buy
- LQDA Strong Buy
- Analyst Count
- ACHC 9
- LQDA 9
- Target Price
- ACHC $47.50
- LQDA $27.67
- AVG Volume (30 Days)
- ACHC 2.1M
- LQDA 2.6M
- Earning Date
- ACHC 08-05-2025
- LQDA 08-12-2025
- Dividend Yield
- ACHC N/A
- LQDA N/A
- EPS Growth
- ACHC N/A
- LQDA N/A
- EPS
- ACHC 1.52
- LQDA N/A
- Revenue
- ACHC $3,229,609,000.00
- LQDA $14,144,000.00
- Revenue This Year
- ACHC $7.80
- LQDA $190.73
- Revenue Next Year
- ACHC $8.56
- LQDA $421.01
- P/E Ratio
- ACHC $12.64
- LQDA N/A
- Revenue Growth
- ACHC 5.64
- LQDA N/A
- 52 Week Low
- ACHC $17.13
- LQDA $8.26
- 52 Week High
- ACHC $82.41
- LQDA $20.63
- Technical
- Relative Strength Index (RSI)
- ACHC 37.45
- LQDA 66.92
- Support Level
- ACHC $17.13
- LQDA $16.82
- Resistance Level
- ACHC $22.51
- LQDA $20.57
- Average True Range (ATR)
- ACHC 1.22
- LQDA 1.32
- MACD
- ACHC -0.40
- LQDA 0.16
- Stochastic Oscillator
- ACHC 35.17
- LQDA 96.56
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.